<div id="readability-page-1"><p>Crescent Park Management L.P. trimmed its holdings in shares of  Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 16.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 570,232 shares of the company's stock after selling 113,179 shares during the period. Cellebrite DI makes up  approximately  3.5% of Crescent Park Management L.P.'s holdings, making the stock its 12th largest position. Crescent Park Management L.P. owned approximately 0.24% of Cellebrite DI worth $9,124,000 as of its most recent SEC filing.</p><p>Several other hedge funds and other institutional investors also recently made changes to their positions in CLBT. T. Rowe Price Investment Management Inc. bought a new position in  Cellebrite DI during the 1st quarter valued at approximately $60,939,000.  Invesco Ltd. grew its stake in shares of  Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after acquiring an additional 1,811,757 shares during the last quarter.  Phoenix Financial Ltd. increased its holdings in shares of  Cellebrite DI by 153.5% during the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company's stock valued at $32,232,000 after acquiring an additional 1,219,958 shares in the last quarter.  Handelsbanken Fonder AB raised its position in shares of  Cellebrite DI by 61.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company's stock worth $39,200,000 after purchasing an additional 931,300 shares during the last quarter.  Finally, Royal Bank of Canada boosted its stake in  Cellebrite DI by 11,705.0% in the 1st quarter. Royal Bank of Canada now owns 824,226 shares of the company's stock worth $16,015,000 after purchasing an additional 817,244 shares in the last quarter. Hedge funds and other institutional investors own  45.88% of the company's stock. </p><div><p><span></span><span>Get <strong>Cellebrite DI</strong> alerts:</span></p></div><h2>Cellebrite DI Price Performance</h2><p>CLBT stock opened at $17.14 on Tuesday. Cellebrite DI Ltd. has a 1 year low of $13.10 and a 1 year high of $26.30. The company has a market cap of $4.10 billion, a P/E ratio of -22.55, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28. The stock's fifty day moving average price is $17.79 and its 200-day moving average price is $16.50. </p><p>Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.13 by ($0.05). The firm had revenue of $126.03 million for the quarter, compared to analysts' expectations of $122.98 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm's revenue was up 17.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 EPS.  Cellebrite DI has set its FY 2025 guidance at  EPS. Q4 2025 guidance at  EPS. As a group, analysts expect that  Cellebrite DI Ltd. will post 0.3 earnings per share for the current year. </p><h2>Analysts Set New Price Targets</h2><p>A number of analysts have weighed in on the stock. Bank of America raised their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 13th. JPMorgan Chase &amp; Co. raised their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, November 13th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Cellebrite DI in a report on Tuesday, November 25th. Lake Street Capital increased their target price on Cellebrite DI from $22.00 to $23.00 and gave the company a &#34;buy&#34; rating in a research note on Thursday, November 13th. Finally, Needham &amp; Company LLC boosted their price target on Cellebrite DI from $22.00 to $24.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $24.00.</p><p><b>Check Out Our Latest Report on CLBT</b></p><h2>Cellebrite DI Company Profile</h2> (Free Report)<p>Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.</p><h2>See Also</h2><ul><li>Five stocks we like better than Cellebrite DI</li><li>There Are Different Types of Stock To Invest In</li><li>Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity</li><li>Canadian Penny Stocks: Can They Make You Rich? </li><li>Congress Beat the Market Again—Here Are the 3 Stocks They Bought</li><li>Consumer Discretionary Stocks Explained</li><li>Go on a Shopping Spree With 3 Top Retail ETFs</li></ul><p><strong>Want to see what other hedge funds are holding CLBT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cellebrite DI Right Now?</h2><p>Before you consider Cellebrite DI, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.</p><p>While Cellebrite DI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CLBT

<p>Crescent Park Management L.P. reduced its stake in Cellebrite DI Ltd. by 16.6% in Q2, now holding 570,232 shares. Other institutional investors also adjusted their positions in CLBT. The stock opened at $17.14 with a market cap of $4.10 billion. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and an average target price of $24.00.</p>

Crescent Park Management L.P. Cuts Position in Cellebrite DI Ltd. $CLBT